The episode celebrates and reflects on International #NASHDay 2023 with a panel of patient advocates (Michael Betel, Gina Villiotti Madison and Marko Korenjak) and co-hosts Louise Campbell and Roger Green. Each speaks to what the day means to them and the group explores how the community is taking action to step up to a public health epidemic.
To kick off International #NASHDay 2023, Surfing NASH starts its ongoing coverage with an episode dedicated to a momentous and fitting announcement. William Alazawi and Vanessa Hebditch join Louise Campbell and Roger Green to celebrate and comment on evidence-based guidance on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care in the UK.
Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation captures closing comments and thoughts on building the innovative program into the future.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation looks into the second day of the conference and the impact that the FDA ADCOM on obeticholic acid has on all of these issues discussed.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation takes a deeper dive into what constitutes ‘preventative hepatology.’ The group teases out multiple concepts of what this could or should look like.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation considers alcohol consumption and its impact on NAFLD. Additionally, the group discusses applying FibroScan in different patient settings.
The opening conversation sets the stage for the 2023 Innovations in NAFLD Care Workshop held in Barcelona from 26-27 May, 2023. Conference founders and directors Jeff Lazarus and Jörn Schattenberg discuss this year’s goals of the event and facilitating the hands-on NASH-NITs Real-World-Evidence Summit.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This final conversation explores hepatocellular ballooning and the power of AI-assisted pathological assessment.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This conversation considers how to lower screen fail rates and the prospect of establishing guidelines for the biopsy reading process.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. This conversation features Stephen’s take on the recent outcome of the FDA ADCOM meeting for obeticholic acid (OCA) as a treatment for pre-cirrhotic fibrosis due to NASH.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.
Donna Cryer joins Jörn Schattenberg and Roger Green for a session which draws from raw reflections on the recent FDA Advisory Committee meeting and its outcome for obeticholic acid. The group remains focused on a critical message that looks down the path forward for the liver community and meeting patient needs. Stay tuned for more coverage as SurfingNASH continues to meet with other KOLs and stakeholders to discuss the event and its implications.
New guest Aleksander Krag joins Sven Francque and the surfers to discuss the upcoming EASL Congress in Vienna.
Program speakers Mazen Noureddin, Sven Francque and Hannes Hagström join Roger Green, on-site from Dublin to review their thoughts and key takeaways immediately after the NAFLD Summit ended. In this conversation From the Vault, the group discusses NITs and what will change between now and when this conference convenes next year.
In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This final conversation elaborates on the myriad abilities possessed by the patient community which can be deployed to the fight against Fatty Liver diseases.
In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This conversation places emphasis on what can be done today to support patient needs.
In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This conversation focuses around what’s required to recruit all stakeholders to recognize the reality of this disease for patients and their needs.
In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. In this conversation, Louise Campbell expands on the critical role of nurses as advocates with the unique ability to bridge the patient-physician gaps.
In an honest discussion with Donna Cryer, Surfing NASH explores the challenges of championing patient-centricity and the importance of allied health as many impending and important decisions come to a head for the NAFLD/NASH community. This introductory conversation features an impactful statement from Donna on the gravity surrounding these milestone moments and why patient inputs should be held paramount.
Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation asks (and attempts to answer) whether the REGENERATE reanalysis is likely to succeed in getting the drug approved.
Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this final conversation, each describes the most important thing they would like ICER to learn before another NASH drug analysis.
Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. In this conversation, the panelists dive into why they shared their specific testimonies among other takeaways.
Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.
Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session around the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This opening conversation reveals how each guest became involved in the process and offers a preview of their reactions to the experience.
Patient advocates and friends of the podcast Mike Betel (Fatty Liver Alliance), Tony Villiotti (NASHkNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join co-hosts Louise Campbell and Roger Green to share a range of impressions on a public comments session regarding the draft report released by the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH.
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation From the Vault answers the question “What Can Be Done Today?” in terms of screening and patient management without approved drugs.
Cyrielle Caussy and the Surfers explore final thoughts on identifying NAFLD/NASH patients earlier on in endocrinology settings and the role of allied health professionals in making this possible. Finally, each panelist is asked what they would do if they had a magic wand to touch one thing in their hospital to make a change.
Cyrielle Caussy and the Surfers explore the strength of simple tools that closely link consequence to physicians and push for the identification and risk stratification of respective patient populations. This session also entertains with a fascinating anecdote on the famous composer, Beethoven, and his liver health.
Cyrielle Caussy joins the Surfers to talk about how patients can be motivated by biofeedback to improve both liver health and overall condition. Following, the group discusses how specific phenotypes in chronic kidney patients can be targeted for high risk of NAFLD/NASH.
In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. This conversation features Cyrielle Caussy alongside Surfers Jörn Schattenberg, Louise Campbell and Roger Green discussing why endocrinology clinics are a critical setting for early identification of patients with NAFLD and NASH.
In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy to discuss interprofessional collaboration, education and awareness on Fatty Liver disease and early identification of at-risk populations.
As part of ongoing dialogue around clinical care pathways and the complex of metabolic diseases, SurfingNASH dedicates a session to focus on the key relationship and interplay between endocrinology and hepatology. Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy to discuss interprofessional collaboration and education for early identification of at-risk populations.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this final conversation the group summarizes their thoughts and suggests what will be discussed on the 6th Anniversary Special in 2026. At the end of the episode, there is a birthday surprise.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group continues to discuss the trajectory of liver science, drug development, driving education, clinical trials and more.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group dives into the tremendous progress being made in liver science and ultimately building a roadmap to therapy.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group shares recollections of their introductions to the podcast as we play throwback clips to their debut appearances.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation, Stephen shares his latest work and interests before the group listens and reacts to a clip of the original introduction featured on earlier episodes.
As part of a Surfing NASH 3rd Anniversary Special, Louise Campbell and Roger Green interview CEO and Co-Founder of Inventiva Pharma, Frédéric Cren, to explore the trajectory of NASH therapeutics and Inventiva’s lead product candidate, lanifibranor.
As part of a Surfing NASH 3rd Anniversary Special, Louise Campbell and Roger Green interview CEO and Founder of the Global Liver Institute, Donna Cryer, to discuss the last three years and the future of fighting fatty liver disease.
As part of the podcast’s 3rd Anniversary Special, Louise Campbell and Roger Green interview Amy Articolo of Novo Nordisk to discuss the last three years and the future of fighting fatty liver disease.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the Surfers and interviewees Amy Articolo, Donna Cryer and Frédéric Cren.
In this episode From the Vault, The SurfingNASH team (Jörn Schattenberg, Louise Campbell, Roger Green) join Global Liver Institute NASH Programs Director Jeff McIntyre for the wrap-up panel of #NASHDay 2022.
The Surfers brainstorm ways we can all Step Up to NASH as the global liver community approaches #NASHDay on June 8th.
The Surfers discuss ways which different communities can become involved in #NASHDay 2023.
The Surfers explore elements of 2022 that have produced ripples in the pond of liver disease. Donna Cryer speaks to seeding investments in the global community and how these partnerships have made a measurable impact for the field.
Donna Cryer shares this year’s #NASHDay theme, Step Up to NASH, while Pamela Danagher and Jörn Schattenberg offer their first takes on what makes June 8th so special.
Donna Cryer describes Global Liver Institute’s journey of growing #NASHDay over the last six years and strengthening its impact on fighting fatty liver with an engaged global community.
As a momentous year for NASH unfolds, the Surfers (Donna Cryer, Pam Danagher, Jörn Schattenberg and Roger Green) preview #NASHDay 2023 and discuss what activities and energies are leading up to the event.
In this conversation From the Vault, Quentin Anstee joins the Surfers (including Stephen Harrison) to discuss two recent presentations on NITs and to consider goals and applications for NASH Biomarkers.
Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this final conversation, the group shares takeaways from the published slides that they feel will be worth reviewing for those who couldn’t join the meeting live.
Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this conversation, the group revisits a perspective-shifting session titled “A New Look at Statistics.”
Co-hosts Jörn Schattenberg and Roger Green review Liver Forum 14 with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. For this conversation, each panelist picks a session that captured their interest and Mazen provides a flavor of his talk on Compensated Cirrhosis Risk Stratification.
Co-hosts Jörn Schattenberg and Roger Green review Liver Forum 14 with Executive Director Veronica Miller and speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. In this conversation, Veronica recaps the aims of the Forum and each panelist shares their initial reactions around what makes the meeting special.
Co-hosts Jörn Schattenberg and Roger Green review the 2023 Liver Forum with Executive Director Veronica Miller. Joining the session are meeting speakers Mazen Noureddin, Michelle Long and Jeff McIntyre. The group highlights how the event embodies truly integrative thinking.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this final conversation, the group share their interests around what’s to come for the second quarter in Fatty Liver.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group share thoughts around drug development and the possibility of new Phase 3 press releases on the imminent horizon. Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group share thoughts around drug development and the possibility of new Phase 3 press releases on the imminent horizon.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, the group discuss NICE and FibroScan in the primary care setting, frontline screening to enable early detection and prevent cirrhosis, the upcoming EASL Congress and more.
Co-hosts Jörn Schattenberg, Louise Campbell and Roger Green convene to discuss what’s happening for fatty liver so far in 2023 and moving into the second quarter. In this conversation, Jörn describes his attendance at the 3rd Annual Liver Connect Conference in California.
This week, co-hosts Jörn Schattenberg, Louise Campbell and Roger Green discuss the 3rd Annual Liver Connect Conference, NICE approval process for FibroScan in primary care, updates in the therapeutic pipeline, pathways and the Surfing NASH 4th anniversary special. The session is fun and full of surprises – like a new metaphor from Roger to describe fatty liver disease.
On May 6 and 7 2022, over 100 NAFLD stakeholders convened in Barcelona and online for the inaugural Innovations in NAFLD Care 2022 conference (#INCBCN.) This episode comes from the Surfing NASH coverage and to preview the upcoming 2023 Workshop.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation investigates what sort of impact the Workshop will have in the imminent future and the factors that will determine its success.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation explores qualities which set the event apart from others and expands on its interactive emphasis.
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation introduces themes and sessions from Day 2 in Barcelona, including a debate on diet: can vegetarianism cure NAFLD?
Surfing NASH previews the 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation continues to introduce themes and sessions from Day 1 in Barcelona on May 26. The group dives in-dept to the linkage between Fatty Liver and cancers, and the importance of early liver health screening for cancer prevention.
